Table 1 Characteristics of the patients at baseline
CharacteristicAlbendazole (n = 88)Placebo (n = 90)
Demographic information
    Age (y) (mean (SE))39.39 (17.79)41.55 (16.80)
    Children (<18 y) (No (valid %))8 (9.2)7 (8.0)
    Males (No (valid %))51 (58.6)46 (52.9)
    Females (No (valid %))36 (41.4)41 (47.1)
    Missing age and gender information (n)13
Cyst phase and location
    Active cysts (No (valid %))59 (68.6)57 (66.3)
    Transitional (No (valid %))49 (57.0)54 (66.8)
    Calcifications (No (valid %))38 (44.2)32 (37.2)
    Parenchymal cysts (No (valid %))74 (86.0)74 (82.2)
        Active parenchymal cysts45 (52.3)39 (45.3)
        Transitional parenchymal cysts40 (46.5)52 (60.5)
        Calcified parenchymal cysts35 (40.7)31 (36.0)
    Extraparenchymal cysts (No (valid %))35 (40.7)42 (48.8)
        Active extraparenchymal cysts28 (32.6)30 (34.9)
        Transitional extraparenchymal cysts11 12.8)13 15.1)
        Calcified parenchymal cysts7 (8.1)7 (8.1)
    Missing baseline scan (n)24
Most common symptoms
    Headache (No (valid %))60 (68.2)64 (71.1)
    Seizures (No (valid %))51 (59.3)56 (64.4)
    Dizziness (No (valid %))16 (18.6)28 (32.2)
    Gait problems (No (valid %))13 (15.1)17 (19.5)
    Limb weakness (No (valid %))13 (15.1)9 (10.3)
    Depression and/or anxiety (No (valid %))15 (15.1)17 (19.5)
  • *Categories are not mutually exclusive; patients may have had cysts of more than one type and in more than one location and may have experienced multiple symptoms.